Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall Reuters
🎗️
Онкология
🎗️Лента новостей
🎗️
Онкология
Molecular Glue Shows Promise Against Aggressive Uterine Cancer | Case Comprehensive Cancer Center
Molecular Glue Shows Promise Against Aggressive Uterine Cancer | Case Comprehensive Cancer Center Case Western Reserve University
Онкология
Experimental mRNA vaccine cuts risk melanoma returns by 42%
Experimental mRNA vaccine cuts risk melanoma returns by 42% CNN
Онкология
Study reveals how melanoma outmaneuvers both drugs and immune defenses
Melanoma is one of the most difficult cancers to treat due to its resistance to targeted drug therapies. But a new study from the University of Kentucky Markey Cancer Center shows that the cancer is playing offense as well as defense: In addition to forming resistance against the MAPK inhibitors that are commonly used…
Онкология
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials CancerNetwork
🎗️
Онкология
Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report The New York Times
Онкология
New AI platform helps uncover promising cancer drug combinations
UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.
Онкология
«Я не хочу умирать!»: плачущая Лерчек сообщила о резком ухудшении состояния и распространении метастаз
«Я не хочу умирать!»: плачущая Лерчек сообщила о резком ухудшении состояния и распространении метастаз Вокруг ТВ
Онкология
UH Cancer Center expands cancer care statewide with $2.5M Helmsley grant
UH Cancer Center expands cancer care statewide with $2.5M Helmsley grant University of Hawaii System
Онкология
Prostate Cancer Drug Shows Promise in New Clinical Trial
Prostate Cancer Drug Shows Promise in New Clinical Trial Yale School of Medicine
Онкология
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results BioPharma Dive
Онкология
No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up
A short course of neoadjuvant immunotherapy continues to show long-term outcomes in patients with locally advanced mismatch repair–deficient (dMMR) colon cancer. In the NICHE-2 study, none of the 111 patients in the primary efficacy population experienced disease recurrence, and all were alive at their most recent…
Онкология
Itziar Canamasas: Why Tumor Biology Matters in Precision Oncology
Itziar Canamasas: Why Tumor Biology Matters in Precision Oncology Oncodaily
Онкология
Акции Moderna обвалились на 25% за день из-за утечки данных о вакцине против рака
Акции Moderna обвалились на 25% за день из-за утечки данных о вакцине против рака TradingView